Amy Q Lei, MD
Hematology/Oncology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 2
Offices
2 locations · Permanente Medical Group Inc · 10,928 clinicians in this group
Looking this up.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lei’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A102303 · Current
Licensed to practise in California · since 2007 · expires 2027-03-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$3,210,181
Pharmacies billed $3,210,181 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (31 of 697) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 45% of their opioid prescriptions.
474 generic and fewer than 11 brand-name prescriptions · $3,210,181 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ibrance | 109 | $1,686,693 | $15,474 |
| Verzenio | 19 | $304,266 | $16,014 |
| Brukinsa | 20 | $262,699 | $13,135 |
| Tagrisso | 13 | $223,310 | $17,178 |
| Lynparza | 19 | $159,631 | $8,402 |
See all 16 drugs
| Ibrance | 109 | $1,686,693 | $15,474 |
| Verzenio | 19 | $304,266 | $16,014 |
| Brukinsa | 20 | $262,699 | $13,135 |
| Tagrisso | 13 | $223,310 | $17,178 |
| Lynparza | 19 | $159,631 | $8,402 |
| Alvaiz | 11 | $94,089 | $8,554 |
| Letrozole | 206 | $4,088 | $20 |
| Exemestane | 32 | $2,602 | $81 |
| Tamoxifen Citrate | 34 | $896 | $26 |
| Erlotinib | 11 | $818 | $74 |
| Morphine Sulfate Er | 12 | $585 | $49 |
| Imatinib Mesylate | 12 | $564 | $47 |
| Anastrozole | 18 | $517 | $29 |
| Hydrocodone-Acetaminophen | 11 | $435 | $40 |
| Gabapentin | 13 | $319 | $25 |
| Bicalutamide | 11 | $295 | $27 |
Year by year
| 2024 | 697 | 179 | 4% (31) | None | $3,210,181 |
| 2023 | 650 | 161 | 3% (21) | None | $1,686,981 |
| 2022 | 757 | 184 | 6% (46) | None | $1,973,549 |
| 2021 | 692 | 150 | 6% (41) | None | $2,245,690 |
| 2020 | 772 | 173 | 7% (51) | 21% | $1,916,889 |
| 2019 | 961 | 198 | 8% (81) | None | $1,922,194 |
| 2018 | 866 | 192 | 9% (80) | None | $1,406,712 |
| 2017 | 785 | 170 | 10% (75) | None | $660,747 |
| 2016 | 766 | 180 | 9% (65) | None | $502,862 |
| 2015 | 688 | 153 | 8% (56) | 26% | $876,473 |
| 2014 | 402 | 104 | 3% (11) | 21% | $179,984 |
| 2013 | 196 | 52 | 15% (30) | 30% | $120,361 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Ibrance | 50 | $700,246 | $14,005 |
| Stivarga | 11 | $211,081 | $19,189 |
| Tagrisso | 11 | $181,399 | $16,491 |
| Lynparza | 22 | $177,972 | $8,090 |
| Brukinsa | 12 | $154,110 | $12,842 |
| Promacta | 11 | $140,424 | $12,766 |
| Letrozole | 209 | $3,885 | $19 |
| Exemestane | 49 | $3,195 | $65 |
| Tamoxifen Citrate | 36 | $1,152 | $32 |
| Anastrozole | 32 | $773 | $24 |
| Hydroxyurea | 21 | $766 | $36 |
| Alendronate | 23 | $235 | $10 |
| Baclofen | 11 | $164 | $15 |
2022: 12 drugs
| Ibrance | 89 | $1,165,904 | $13,100 |
| Stivarga | 13 | $215,475 | $16,575 |
| Tagrisso | 11 | $185,551 | $16,868 |
| Brukinsa | 11 | $139,246 | $12,659 |
| Letrozole | 252 | $5,165 | $20 |
| Exemestane | 41 | $3,308 | $81 |
| Tamoxifen Citrate | 28 | $1,476 | $53 |
| Hydroxyurea | 18 | $674 | $37 |
| Anastrozole | 26 | $614 | $24 |
| Hydrocodone-Acetaminophen | 18 | $409 | $23 |
| Gabapentin | 12 | $347 | $29 |
| Alendronate | 22 | $229 | $10 |
2021: 14 drugs
| Ibrance | 120 | $1,510,324 | $12,586 |
| Tagrisso | 17 | $282,102 | $16,594 |
| Letrozole | 213 | $5,119 | $24 |
| Exemestane | 44 | $3,867 | $88 |
| Imatinib Mesylate | 13 | $2,304 | $177 |
| Tamoxifen Citrate | 27 | $1,442 | $53 |
| Hydroxyurea | 14 | $586 | $42 |
| Anastrozole | 18 | $438 | $24 |
| Dexamethasone | 12 | $404 | $34 |
| Hydrocodone-Acetaminophen | 17 | $352 | $21 |
| Gabapentin | 13 | $350 | $27 |
| Baclofen | 11 | $245 | $22 |
| Alendronate | 22 | $229 | $10 |
| Oxycodone | 12 | $170 | $14 |
2020: 18 drugs
| Ibrance | 63 | $795,392 | $12,625 |
| Piqray | 16 | $285,460 | $17,841 |
| Tagrisso | 13 | $213,450 | $16,419 |
| Imbruvica | 12 | $160,848 | $13,404 |
| Exemestane | 71 | $19,050 | $268 |
| Letrozole | 230 | $5,588 | $24 |
| Imatinib Mesylate | 15 | $2,231 | $149 |
| Tamoxifen Citrate | 31 | $1,630 | $53 |
| Hydroxyurea | 16 | $800 | $50 |
| Anastrozole | 22 | $542 | $25 |
| Gabapentin | 13 | $527 | $41 |
| Morphine Sulfate Er | 11 | $525 | $48 |
| Baclofen | 11 | $428 | $39 |
| Hydrocodone-Acetaminophen | 19 | $409 | $22 |
| Alendronate | 24 | $250 | $10 |
| Omeprazole | 11 | $167 | $15 |
| Oxycodone | 11 | $153 | $14 |
| Lorazepam | 11 | $77 | $7 |
2019: 22 drugs
| Ibrance | 60 | $773,976 | $12,900 |
| Tagrisso | 21 | $337,480 | $16,070 |
| Lorbrena | 13 | $227,732 | $17,518 |
| Exemestane | 88 | $27,878 | $317 |
| Xarelto | 13 | $9,200 | $708 |
| Letrozole | 244 | $5,991 | $25 |
| Enoxaparin | 19 | $3,489 | $184 |
| Imatinib Mesylate | 16 | $2,744 | $172 |
| Fentanyl | 15 | $2,137 | $142 |
| Tamoxifen Citrate | 33 | $1,706 | $52 |
| Hydroxyurea | 15 | $1,196 | $80 |
| Gabapentin | 24 | $947 | $39 |
| Anastrozole | 27 | $638 | $24 |
| Hydrocodone-Acetaminophen | 34 | $574 | $17 |
| Morphine Sulfate Er | 14 | $558 | $40 |
| Duloxetine | 13 | $317 | $24 |
| Diphenoxylate-Atropine | 13 | $283 | $22 |
| Alendronate | 20 | $216 | $11 |
| Ondansetron | 20 | $193 | $10 |
| Prednisone | 12 | $192 | $16 |
| Omeprazole | 11 | $188 | $17 |
| Lorazepam | 18 | $140 | $8 |
2018: 18 drugs
| Ibrance | 41 | $504,617 | $12,308 |
| Tagrisso | 30 | $429,977 | $14,333 |
| Afinitor | 13 | $203,910 | $15,685 |
| Exemestane | 94 | $28,928 | $308 |
| Imatinib Mesylate | 13 | $5,446 | $419 |
| Letrozole | 217 | $5,374 | $25 |
| Fentanyl | 21 | $3,063 | $146 |
| Enoxaparin | 11 | $2,805 | $255 |
| Hydroxyurea | 17 | $1,982 | $117 |
| Tamoxifen Citrate | 33 | $1,671 | $51 |
| Dexamethasone | 17 | $805 | $47 |
| Anastrozole | 32 | $797 | $25 |
| Hydrocodone-Acetaminophen | 32 | $554 | $17 |
| Ondansetron | 27 | $346 | $13 |
| Oxycodone | 14 | $300 | $21 |
| Acyclovir | 12 | $268 | $22 |
| Lorazepam | 20 | $171 | $9 |
| Alendronate | 13 | $161 | $12 |
2017: 19 drugs
| Ibrance | 17 | $203,434 | $11,967 |
| Exemestane | 78 | $29,099 | $373 |
| Imatinib Mesylate | 13 | $13,616 | $1,047 |
| Letrozole | 195 | $5,090 | $26 |
| Hydroxyurea | 22 | $2,666 | $121 |
| Tamoxifen Citrate | 33 | $1,739 | $53 |
| Hydrocodone-Acetaminophen | 32 | $1,366 | $43 |
| Fentanyl | 11 | $1,351 | $123 |
| Diphenoxylate-Atropine | 17 | $788 | $46 |
| Gabapentin | 15 | $718 | $48 |
| Anastrozole | 24 | $667 | $28 |
| Acyclovir | 22 | $389 | $18 |
| Morphine Sulfate Er | 13 | $360 | $28 |
| Dexamethasone | 16 | $352 | $22 |
| Ondansetron | 23 | $343 | $15 |
| Oxycodone | 11 | $252 | $23 |
| Lorazepam | 26 | $231 | $9 |
| Prochlorperazine Maleate | 19 | $200 | $11 |
| Prednisone | 14 | $151 | $11 |
2016: 19 drugs
| Revlimid | 17 | $136,749 | $8,044 |
| Gleevec | 12 | $76,094 | $6,341 |
| Exemestane | 46 | $20,630 | $448 |
| Letrozole | 202 | $7,389 | $37 |
| Lovenox | 16 | $7,024 | $439 |
| Zenpep | 12 | $6,815 | $568 |
| Hydroxyurea | 28 | $2,654 | $95 |
| Hydrocodone-Acetaminophen | 25 | $1,507 | $60 |
| Oxycodone | 18 | $1,467 | $81 |
| Gabapentin | 20 | $1,359 | $68 |
| Tamoxifen Citrate | 21 | $1,182 | $56 |
| Anastrozole | 32 | $1,084 | $34 |
| Diphenoxylate-Atropine | 16 | $586 | $37 |
| Dexamethasone | 14 | $433 | $31 |
| Lorazepam | 46 | $397 | $9 |
| Ondansetron | 17 | $313 | $18 |
| Prednisone | 24 | $199 | $8 |
| Prochlorperazine Maleate | 14 | $179 | $13 |
| Zolpidem | 11 | $83 | $8 |
2015: 17 drugs
| Revlimid | 57 | $503,806 | $8,839 |
| Zytiga | 19 | $151,046 | $7,950 |
| Exemestane | 27 | $16,204 | $600 |
| Lovenox | 27 | $15,487 | $574 |
| Letrozole | 124 | $4,820 | $39 |
| Hydroxyurea | 22 | $2,385 | $108 |
| Hydrocodone-Acetaminophen | 26 | $2,194 | $84 |
| Gabapentin | 17 | $997 | $59 |
| Anastrozole | 25 | $883 | $35 |
| Tamoxifen Citrate | 12 | $722 | $60 |
| Dexamethasone | 17 | $667 | $39 |
| Diphenoxylate-Atropine | 14 | $591 | $42 |
| Prednisone | 28 | $536 | $19 |
| Ondansetron | 28 | $505 | $18 |
| Acyclovir | 14 | $408 | $29 |
| Lorazepam | 39 | $337 | $9 |
| Prochlorperazine Maleate | 29 | $325 | $11 |
2014: 10 drugs
| Lovenox | 14 | $8,655 | $618 |
| Exemestane | 16 | $6,707 | $419 |
| Spiriva | 11 | $2,831 | $257 |
| Letrozole | 78 | $2,622 | $34 |
| Ondansetron | 35 | $698 | $20 |
| Gabapentin | 15 | $514 | $34 |
| Acyclovir | 13 | $478 | $37 |
| Prochlorperazine Maleate | 39 | $418 | $11 |
| Bicalutamide | 11 | $271 | $25 |
| Prednisone | 14 | $181 | $13 |
2013: 2 drugs
| Letrozole | 13 | $480 | $37 |
| Prochlorperazine Maleate | 12 | $125 | $10 |
Money from drug and device companies
$23 in 2025
A payment is not proof that care is biased.
| Hologic Sales and Service | Thinprep 2000 Processor | $23 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2025-03-01 | Thinprep 2000 Processor | $23 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment To Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib · 2025 | Their institution | $10,000 |
| Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2021 | Their institution | $42 |
Professional record
- NPI
- 1376726059
- Licence
- CA A102303California A102303: Current · expires 2027-03-31
- Trained
- Washington University School of Medicine, 2006
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 4150 V St, Suite # 3116, Sacramento, CA, 95817
- NPI first listed
- 2007-12-17
- NPI last updated
- 2022-02-11
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.